Cashu
Alkermes plc Launches Pathways Research Awards to Boost Neuroscience Innovation and Research
about 5 hours ago
Stocks
Health Care
alks
Alkermes plc
NASDAQ: ALKS
+0.78 (+2.90%)
27.71
USD
At close at Sep 11, 20:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
4.44B
Dividend Yield
0.00%
P/E Ratio
12.74
EPS
2.23
Revenue
1.56B
Avg. Volume
3.27M
About
What does ALKS do?
Alkermes Plc is a biopharmaceutical company based in Dublin, focused on developing treatments for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, employing 2,100 people. Its key products include LYBALVI, ARISTADA, and VIVITROL, with ongoing development for neurological disorders and cancer.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.